REZUROCK

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug REZUROCK contains one active pharmaceutical ingredient (API):

1	Belumosudil UNII 6MX7XE1M0U - BELUMOSUDIL MESYLATE
	Belumosudil is a serine/threonine kinase inhibitor indicated for the treatment of chronic graft-versus-host disease (chronic GVHD). Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signaling pathways which play major roles in pro- and anti-inflammatory immune cell responses.
	Read more about Belumosudil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REZUROCK Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA48		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA48

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02526115
US	FDA, National Drug Code	79802-200